Fascin蛋白在甲状腺乳头状癌中的表达及其临床意义

目的 通过检测Fascin蛋白在正常甲状腺组织、甲状腺良性病变及甲状腺乳头状癌中的表达水平,探讨该蛋白对甲状腺癌诊断和治疗的意义。方法 应用免疫组织化学方法,检测60例甲状腺乳头状癌(其中23例伴有淋巴结转移)、40例甲状腺良性肿瘤(甲状腺腺瘤及结节性甲状腺肿)以及20例取自甲状腺良性病变旁的正常甲状腺组织中Fascin蛋白的表达水平差异,分析Fascin蛋白表达水平与患者性别、年龄、有无淋巴结转移等临床特征的关系。结果 Fascin蛋白在甲状腺乳头状癌中的表达率(71.67%)明显高于良性甲状腺病变组及正常甲状腺组织组,三者之间比较差异有显著统计学意义(P＜0.01);甲状腺良性病变患者的甲状腺组织与正常甲状腺组织相比较,Fascin蛋白表达的阳性率均为零,差异无统计学意义(P＞0.05)。甲状腺乳头状癌伴淋巴结转移组中,Fascin蛋白的阳性表达率为91.30%,明显高于无淋巴结转移组(59.46%),两组之间比较差异具有统计学意义(P＜0.05)。结论 Fascin蛋白的表达与甲状腺乳头状癌的发生、发展及淋巴结转移密切相关,可以为甲状腺病变的良、恶性诊断,判断肿瘤的生物学行为及其预后提供理论依据,为临床治疗提供新的靶点。

Research on the expression of protein Fascin in thyroid papillary carcinoma and significance

Objective To investigate the expression of protein fascin in normal thyroid tissues,thyroid benign lesions and thyroid papillary carcinoma and to evaluate their clinical significance. Methods The expres- sion of protein fascin was determined in 60 patients with thyroid papillary carcinoma,40 of thyroid adenoma and nodular goiter and 20 of normal thyroid tissues by histochemical method （SP） , then these values were compared among each other. Results The positive rate of fascin protein in thyroid papillary carcinoma（71.67% ）was higher than that in thyroid benign lesions and normal thyroid tissues ,there was significant difference between them（ P 〈 0.01 ）. The positive rate in thyroid benign lesions was not higher than that in normal thyroid tissues, there was no significant difference（ P 〉 0.05 ）. In thyroid papillary carcinoma with lymphatic metastasis, the positive expression of fascin protein significantly increased（91.30% ）. There was significant difference compared with no lymphatic metastasis （59.46%）, （P 〈 0.05 ）. Conclusions The expression of fascin protein is correlated to the incidence, invasion and metastasis of thyroid papillary carcinoma and it may provide theoretical evidence for identification between benign diseases and thyroid carcinoma,it is also helpful for evaluating the behaviour of thyroid papillary carcinoma. The potiential of fascin protein as a novel early diagnostic marker and therapeutic target is assessed in thyroid carcinoma.